Krystal Biotech (KRYS) closed at $298.55 on November 17, 2026, up 0.2% from the previous close, on volume of 128,804 shares (30-day average 285,264).
Data as of November 17, 2026.
17-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 16, 2026 | Diagonal Call Spread | 20-Nov : 18-Dec-26340 : 320 C | 1,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Globe Newswire (Tue, 17-Nov 5:38 PM ET)
Krystal Biotech Earnings Call Signals Durable Growth and Pipeline Progress
TipRanks (Sat, 14-Nov 9:06 PM ET)
Krystal Biotech to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
Globe Newswire (Thu, 22-Oct 8:00 AM ET)
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Market Chameleon (Mon, 3-Aug 3:54 AM ET)
Market Chameleon (Mon, 4-May 5:43 AM ET)
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Krystal Biotech trades on the NASDAQ stock market under the symbol KRYS.
As of November 17, 2026, KRYS stock price climbed to $298.55 with 128,804 million shares trading.
KRYS has a beta of 0.91, meaning it tends to be less sensitive to market movements. KRYS has a correlation of 0.11 to the broad based SPY ETF.
KRYS has a market cap of $8.73 billion. This is considered a Mid Cap stock.
Last quarter Krystal Biotech reported $127 million in Revenue and $2.05 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.15.
In the last 3 years, KRYS traded as high as $382.54 and as low as $99.00.
The top ETF exchange traded funds that KRYS belongs to (by Net Assets): IJH, VTI, IWM, VB, XBI.
KRYS has outperformed the market in the last year with a price return of +43.4% while the SPY ETF gained +11.2%. However, in the short term, KRYS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.1% vs -5.0% return in SPY. But in the last 2 weeks, KRYS shares have fared better than the market returning -2.1% compared to SPY -2.9%.
KRYS support price is $291.55 and resistance is $304.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRYS shares will trade within this expected range on the day.